Hertz et al. [94] conducted a retrospective PGx analysis based on 469 ER-positive Caucasian breast cancer patients treated with adjuvant tamoxifen monotherapy to investigate the association between low-activity CYP2D6 genotype and recurrence-free survival (RFS). This evidence concerns the gene ESR1 and breast carcinoma.